US4292432A - Novel aldol derivatives and production thereof - Google Patents

Novel aldol derivatives and production thereof Download PDF

Info

Publication number
US4292432A
US4292432A US06/117,981 US11798180A US4292432A US 4292432 A US4292432 A US 4292432A US 11798180 A US11798180 A US 11798180A US 4292432 A US4292432 A US 4292432A
Authority
US
United States
Prior art keywords
hydroxy
group
bicyclo
derivatives
octane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/117,981
Inventor
Keiichi Ono
Akihiko Sugie
Hajime Kawakami
Junki Katsube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Application granted granted Critical
Publication of US4292432A publication Critical patent/US4292432A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
    • C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/40—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with ozone; by ozonolysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/523—Saturated compounds containing a keto group being part of a ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to novel aldol derivatives which are very useful as intermediates for methanoprostacyclin derivatives, and a novel process for producing the same.
  • PGI 2 which is shown below, inhibits aggregations of blood platelets and is expected to be useful for prevention of intravascular thrombosis, cerebrovascular thrombosis, and transient ischemic episodes.
  • the starting material [II] was provided by oxidative cleavage of the olefin derivative [VI] as described below, which could be easily obtained from the industrially available, cis-4-cyclohexene-1,2-dicarboxylic anhydride by the known procedures [e.g. J.O.C. 41 2238 (1978)].
  • the present invention has provided an efficient and advantageous synthesis of the methanoprostacyclin and it congeners.
  • An object of the present invention is to provide the novel aldol derivative [I] which is useful as an intermediate for the production of the methanoprostacyclin and its congeners.
  • Another object of this invention is to provide a novel and excellent synthetic method for producing the aldol derivative [I].
  • Oxidation of the olefin derivative [VI] into the dialdehyde derivative [II] can be accomplished by treatment with sodium metaperiodate in the presence of a catalytic amount of osmium tetroxide in an inert solvent at a range of the temperature from 0° C. to room temperature.
  • the inert solvent include water, ethers (e.g. dioxane, tetrahydrofuran) and aqueous ethers.
  • the dialdehyde derivative [II] can be also obtained by ozonization at a range of temperature from -80° C. to -30° C., followed by reductive cleavage with dialkyl sulfide, triphenylphosphine, sodium bisulfite, zinc or the like, or by catalytic hydrogenation in the presence of palladium on charcoal.
  • inert solvent for ozonization examples include alkanols (e.g. methanol, ethanol), halogenated hydrocarbons and ethers.
  • Reduction of an ozonide may be accomplished by a, per se, conventional procedure at a range of temperature from -30° C. to room temperature.
  • Aldol condensation of the dialdehyde [II] into the aldol derivative [I] is carried out in the presence of an acid or a base in an inert solvent such as water, alkanols, aqueous alkanols, ethers, and esters at a temperature ranging from -70° C. to room temperature.
  • an inert solvent such as water, alkanols, aqueous alkanols, ethers, and esters
  • alkali hydroxide e.g. potassium hydroxide, sodium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide zinc hydroxide
  • alkali carbonate alkali hydrogen carbonate and triethylamine
  • mineral acids or organic acids examples of the suitable base.
  • aldol derivative [I] are as follows:
  • dialdehyde (1.0 g) obtained above (example 1 or 2) was dissolved in methanol (30 ml) and cooled at -15° ⁇ -5° C.
  • dialdehyde (0.7 g) obtained above (example 1 or 2) was dissolved in methanol (17 ml). To this solution was added 5% aqueous barium hydroxide at 0° ⁇ 10° C.
  • the alcohol obtained above was dissolved into a mixed solvent of acetic acid, water and tetrahydrofuran (3:1:1).
  • the aqueous solution was washed with ether, acidified with aqueous potassium bisulfate and extracted with ethylacetate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

A process for producing novel aldol derivatives of the formula, ##STR1## wherein C=W is a carbonyl group or a protected carbonyl group which comprises reacting a compound of the formula: ##STR2## wherein C=W is as defined above in the presence of an acid or a base at a temperature ranging from -70° C. to room temperature. The novel aldol derivatives of the above formula are useful as intermediate for producing methanoprostacyclin derivatives which are useful medicines for prevention of thrombosis.

Description

The present invention relates to novel aldol derivatives which are very useful as intermediates for methanoprostacyclin derivatives, and a novel process for producing the same.
The novel aldol derivatives provided by the present invention are those represented by the formula [I]: ##STR3## wherein C=W is a carbonyl group or a protected carbonyl group.
The novel process for producing the aldol derivatives [I] involves the intramolecular aldol cyclization of the dialdehyde derivatives of the formula: ##STR4## wherein C=W is as defined above.
A tremendous amount of research in synthetic organic chemistry, pharmacology and clinical application of prostaglandins has been performed since discovery of prostaglandins.
In 1976, J. Vane of the Wellcome foundation reported isolation and biological effect of prostacyclin [PGI2 ] (A) [(S. Moncada, R. Gryglewski, S. Bunting, and J. R. Vane, Nature (London), 263, 663 (1976)].
PGI2, which is shown below, inhibits aggregations of blood platelets and is expected to be useful for prevention of intravascular thrombosis, cerebrovascular thrombosis, and transient ischemic episodes.
However, PGI2 may not be used as a medicine owing to its instability. ##STR5##
In the course of our study seeking novel PGI2 analogs, the present inventors formed as novel PGI2 analogs, the methanoprostacyclin [B] and its congeners [Tetrahedron Letters, 2607 (1979)], which were found to have potent activities similar to PGI2. Moreover the methanoprostacyclin [B] and its congeners were found to be much more stable as compared with PGI2 itself, and thus, these novel methanoprostacyclin derivatives can be used as practically useful medicines for prevention of thrombosis, especially for prevention of platelet thrombosis induced by the use of prosthetic devices such as artificial heart valves. ##STR6##
As for the synthesis of the methanoprostacyclin [B], two other approaches have also been published from other research groups [Tetrahedron Letters, 433 (1979), J.C.S. Chemical Communications 1067 (1978), Tetrahedron Letters 3743 (1978)]. But, by any of the synthetic approaches stated above, the methanoprostacyclin [B] was very hard to prepare industrially, since the known syntheses were all suffering from some hardships (too many steps or low availability of the starting materials).
Thus, it has been strongly desired to develop more efficient and more advantageous synthetic approaches for the said methanoprostacyclin derivatives.
As the result of our study, the present inventors have found an efficient process for the synthesis of the aldol derivative [I], and the present inventors have also found that this aldol derivative [I] could be converted efficiently to the objective methanoprostacyclin [B] in only four steps without the protection of its hydroxyl group as shown in the following schema: ##STR7## wherein C=W is as defined above.
In the presebnt aldol cyclization of the dialdehyde derivative [II], the desirable one stereoisomer was obtained with good yields and high purity.
On the other hand, the starting material [II] was provided by oxidative cleavage of the olefin derivative [VI] as described below, which could be easily obtained from the industrially available, cis-4-cyclohexene-1,2-dicarboxylic anhydride by the known procedures [e.g. J.O.C. 41 2238 (1978)].
Thus, the present invention has provided an efficient and advantageous synthesis of the methanoprostacyclin and it congeners.
An object of the present invention is to provide the novel aldol derivative [I] which is useful as an intermediate for the production of the methanoprostacyclin and its congeners.
Another object of this invention is to provide a novel and excellent synthetic method for producing the aldol derivative [I].
According to the present invention, the aldol derivative [I] can be produced advantageously by reacting an olefin derivative of the formula: ##STR8## wherein C=W is a carbonyl group or a protected carbonyl group (e.g. W is an oxygen atom; ethylenedioxy group, an ethylendithio group, a 1,3-propane dioxy group, 2,2-dimethyl-1,3-propanedioxy group, a 1,2-phenylenedioxy group, two methoxy groups) with an oxidizing agent to give a dialdehyde derivative of the formula: ##STR9## wherein C=W is as defined above, followed by the intramolecular cyclization in the presence of an acid or a base.
The process of the present invention will be illustrated below in detail according to the sequence of the reaction steps.
STEP 1 Production of the dialdehyde derivative [II]
Oxidation of the olefin derivative [VI] into the dialdehyde derivative [II] can be accomplished by treatment with sodium metaperiodate in the presence of a catalytic amount of osmium tetroxide in an inert solvent at a range of the temperature from 0° C. to room temperature. Examples of the inert solvent include water, ethers (e.g. dioxane, tetrahydrofuran) and aqueous ethers.
The dialdehyde derivative [II] can be also obtained by ozonization at a range of temperature from -80° C. to -30° C., followed by reductive cleavage with dialkyl sulfide, triphenylphosphine, sodium bisulfite, zinc or the like, or by catalytic hydrogenation in the presence of palladium on charcoal.
Examples of the inert solvent for ozonization include alkanols (e.g. methanol, ethanol), halogenated hydrocarbons and ethers.
Reduction of an ozonide may be accomplished by a, per se, conventional procedure at a range of temperature from -30° C. to room temperature.
STEP 2
Aldol condensation of the dialdehyde [II] into the aldol derivative [I] is carried out in the presence of an acid or a base in an inert solvent such as water, alkanols, aqueous alkanols, ethers, and esters at a temperature ranging from -70° C. to room temperature.
Examples of the suitable base are alkali hydroxide [e.g. potassium hydroxide, sodium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide zinc hydroxide], alkali carbonate, alkali hydrogen carbonate and triethylamine, and as the acid, it is preferable to use mineral acids or organic acids.
Specific examples of the aldol derivative [I] are as follows:
2-β-formyl-3-α-hydroxy-7,7-ethylenedioxycis-bicyclo[3,3,0]octane
2-β-formyl-3-α-hydroxy-7,7-propanedioxycis-bicyclo[3,3,0]octane ##STR10##
2-β-formyl-3-α-hydroxy-7-oxo-cis-bicyclo[3,3,0]-octane
2-β-formyl-3-α-hydroxy-7,7-dimethoxy-cis-bicyclo[3,3,0]octane
2-β-formyl-3-α-hydroxy-7,7-ethylenedithiocis-bicyclo[3,3,0]octane
2-β-formyl-3-α-hydroxy-7,7-(2,2-dimethylpropanedioxy)-cis-bicyclo[3,3,0]octane ##STR11##
2-β-formyl-3α-hydroxy-7,7-phenylenedioxy-cis-bicyclo[3,3,0]octane
Practical and presently preferred embodiments of the invention are illustratively shown in the following examples without limiting the scope of the invention in any way.
EXAMPLE 1
A few milligrams of osmium tetraoxide were added to a solution of 8,8-ethylenedioxy-cis-bicyclo[4,3,0]non-3-ene (1.0 g), water (20 ml) and dioxane (60 ml).
The mixture was stirred for 5 min at room temperature, and to this mixture was added 2.2 g of sodium metaperiodate.
The mixture was further stirred for 20 min. at the same temperature. This reaction mixture was diluted with water and extracted with ether. The organic layer was washed with water, dried and evaporated under reduced pressure to give an oily cis-1,2-diformylmethyl-4,4-ethylenedioxy-cyclopentane.
IR νmax film ; 1725 cm-1
NMR δ(CDCl3); 3.8, 9.7 ppm
EXAMPLE 2
A solution of 8,8-ethylenedioxy-cis-bicyclo[4,3,0]non-3-ene (1.0 g) in methanol (50 ml) was cooled to -50° C. and subjected to a stream of ozonized oxygen. After the starting material had disappeared, 35 ml of dimethylsulfide was added and the mixture was stirred for 2 hr at -5°˜-15° C.
The mixture was then concentrated by introduction of a stream of nitrogen to give an oily cis-1,2-diformylmethyl-4,4-ethylenedioxy-cyclopentane.
The spectral data of the product coincided with that of example 1.
EXAMPLE 3
A solution of the cis-1,2-diformylmethyl-4,4-diethylenedioxy-cyclopentane (1.1 g) in methanol (30 ml) was cooled to -50° C. and treated with 5% aqueous potassium hydroxide, and further stirred at the same temperature. After 4 hr, a saturated solution of sodium chloride and ethylacetate was added to the mixture.
The organic layer was separated, washed with water, dried and concentrated under reduced pressure at a low temperature to give an oily 2-β-formyl-3-α-hydroxy-7,7-ethylenedioxy-cis-bicyclo[3,3,0]octane as a main product.
IR νmax film ; 3400, 1710 cm-1
NMR δ(CDCl3); 3.85, 9.75 ppm
EXAMPLE 4
The dialdehyde (1.0 g) obtained above (example 1 or 2) was dissolved in methanol (30 ml) and cooled at -15°˜-5° C.
A 5% aqueous solution (10 ml) of potassium hydroxide was added, and the mixture was stirred for 13 min. at the same temperature.
The mixture was treated as shown in the example 3 to give an oily 2-β-formyl-3-α-hydroxy-7,7-ethylenedioxy-cis-bicyclo[3,3,0]octane as a main product.
EXAMPLE 5
The dialdehyde (0.7 g) obtained above (example 1 or 2) was dissolved in methanol (17 ml). To this solution was added 5% aqueous barium hydroxide at 0°˜10° C.
After 1 hr at the same temperature, stirring was continued for 40 hr at a room temperature. The mixture was worked up as shown in example 3 or 4 to give an oily 2-β-formyl-3-α-hydroxy-7,7-ethylenedioxy-cis-bicyclo[3,3,0]octane. The spectral data coincided with that of example 3 and there was much less content of the isomer.
REFERENCE EXAMPLE 1
A solution of 2-β-formyl-3-α-hydroxy-7,7-ethylenedioxy-bicyclo[3,3,0]octane (23.3 g) in tetrahydrofuran (30 ml) was added into a tetrahydrofuran solution of ylid prepared with dimethyl 2-oxoheptylphosphonate (29.1 g) and sodium hydride (65% mineral oil dispersion, 4.83 g) and the mixture was stirred for 2 hr at room temperature. Evaporation of the solvent gave an oily residue, to which ether and water was added. The ether layer was separated and dried over magnesium sulfate. The solvent was evaporated and the residue was chromatographed on silica gel to give 2-β-(3'-oxo-trans-1'-octenyl)-3-α-hydroxy-7,7-ethylenedioxy-bicyclo[3,3,0]octane (19.9 g) as an oil.
IR νmax film ; 3400, 1670, 1630 cm-1
NMR δ(CDCl3); 6.68; 6.03; 3.83 ppm
REFERENCE EXAMPLE 2
A methanolic solution of 2β-(3'-oxo-trans-1'-octenyl)-3α-hydroxy-7,7-ethylenedioxy-bicyclo[3,3,0]octane (19.9 g) was treated with sodium borohydride (7.4 g) with ice cooling.
Stirring was continued for 2 hr and excess reducing agent was quenched with acetone, and then the mixture was concentrated under reduced pressure. To the residue was added aqueous ammonium chloride and extracted with ethylacetate.
The organic layer was dried and evaporated to give an oily 2β-(3'-hydroxy-trans-1'-octenyl)-3α-hydroxy-7,7-ethylenedioxy-bicyclo[3,3,0]octane (18 g).
The alcohol obtained above was dissolved into a mixed solvent of acetic acid, water and tetrahydrofuran (3:1:1).
The mixture was warmed at 45° C. and stirred for 4 hr. The solvent was evaporated under reduced pressure and the residue was chromatographed on silica gel to give 2β-(3'β-hydroxy-trans-1'-octenyl)-3α-hydroxy-bicyclo[3,3,0]octane-7-one and 2β-(3'α-hydroxy-trans-1'-octenyl)-3α-hydroxy-bicyclo[3,3,0]octane-7-one.
3'β-hydroxy isomer
IR νmax film ; 3400, 1740 cm-1
NMR δ(CDCl3): 5.60, 0.9 ppm
3'α-hydroxy isomer
IR νmax film ; 3400, 1740 cm-1
NMR δ(CDCl3); 5.53; 0.9 ppm
REFERENCE EXAMPLE 3
A solution of sodium methylsulfinylmethide, prepared from 65% sodium hydride (1.86 g) and dimethylsulfoxide (30 ml), was cooled to 15°˜20° C. and treated with 4-carboxybutyl triphenylphosphonium bromide (11.23 g) under nitrogen.
The mixture was stirred for 10 min at 20° C. To the above ylid solution was added a dimethylsulfoxide solution of 2β-(3'α-hydroxy-trans-1'-octenyl)-3α-hydroxy-bicyclo[3,3,0]octa-7-one (0.84 g) at 20°˜25° C. The reaction mixture was stirred for 6 hr at room temperature, and then diluted with water.
The aqueous solution was washed with ether, acidified with aqueous potassium bisulfate and extracted with ethylacetate.
The extract was washed with brine, dried and concentrated in vacuo to give the residue (2.5 g). The residue was chromatographed on silica gel to give 2β-(3'α-hydroxy-trans-1'octenyl)-3α-hydroxy-7E-(4'-carboxybutylidene)-bicyclo[3,3,0]octane and 2β-(3'α-hydroxy-trans-1'-octenyl)-3α-hydroxy-7Z-(4'-carboxybutylidene)-bicyclo[3,3,0]octane.
7E isomer
IR δmax film ; 3350, 2650, 1710 cm-1
NMR δ(CDCl3); 5.65˜5.4 (2H), 5.1˜5.4 (1H), 4.6˜4.9 (3H)
7Z isomer
IR νmax film ; 3350, 2600, 1710 cm-1
NMR δ(CDCl3); 5.7˜5.45 (2H), 5.0˜5.4 (4H)

Claims (4)

What we claim is:
1. A process for producing a compound of the formula: ##STR12## wherein C=W is a carbonyl group or a protected carbonyl group which comprises reacting a compound of the formula: ##STR13## wherein C=W is as defined above in the presence of an acid or a base at a temperature ranging from -70° C. to room temperature.
2. A process according to claim 1 wherein C=W is a protected carbonyl group.
3. A process according to claim 1 wherein the said base is an alkali hydroxide.
4. A process according to claim 1, wherein the protected carbonyl group is an ethylenedioxy group, an ethylenedithio group, a 1,3-propanedioxy group, a 2,2-dimethyl-1,3-propanedioxy group, a 1,2-phenylenedioxy group or two methoxy groups.
US06/117,981 1979-02-09 1980-02-04 Novel aldol derivatives and production thereof Expired - Lifetime US4292432A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1469079A JPS55105638A (en) 1979-02-09 1979-02-09 Aldol derivative and its preparation
JP54/14690 1979-02-09

Publications (1)

Publication Number Publication Date
US4292432A true US4292432A (en) 1981-09-29

Family

ID=11868184

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/117,981 Expired - Lifetime US4292432A (en) 1979-02-09 1980-02-04 Novel aldol derivatives and production thereof

Country Status (5)

Country Link
US (1) US4292432A (en)
EP (1) EP0015653B1 (en)
JP (1) JPS55105638A (en)
CA (1) CA1142532A (en)
DE (1) DE3060152D1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004019A1 (en) * 1982-05-06 1983-11-24 Cbd Corporation Cycloaliphatic pharmaceutical compounds
WO1985002177A1 (en) * 1983-11-08 1985-05-23 Cbd Corporation Halo bicyclo alkanones
US4681951A (en) * 1983-12-27 1987-07-21 Sagami Chemical Research Center Bicyclo(3.3.0)octene derivatives
US4689345A (en) * 1982-05-06 1987-08-25 Cbd Corporation Oxygenated alkyl substituted bicyclo alkanes
US4689349A (en) * 1982-05-06 1987-08-25 Cbd Corporation Anti-tumor halo bicyclo alkanones

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2040928B (en) * 1978-01-26 1982-12-08 Erba Farmitalia Bicycloalkane derivatives useful as intermediates in preparing pg1 isosteres
JPS58188850A (en) * 1982-04-26 1983-11-04 Sumitomo Chem Co Ltd Novel bicyclooctane derivative and its preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3338969A (en) * 1963-02-27 1967-08-29 Roussel Uclaf A-nor-b-homo-estrane and process of preparation
US4191660A (en) * 1978-02-27 1980-03-04 International Flavors & Fragrances Inc. Organoleptic uses of 1-(3,3-dimethyl-2-norbornyl)-2-propanone in cationic, anionic and nonionic detergents and soaps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2040928B (en) * 1978-01-26 1982-12-08 Erba Farmitalia Bicycloalkane derivatives useful as intermediates in preparing pg1 isosteres

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3338969A (en) * 1963-02-27 1967-08-29 Roussel Uclaf A-nor-b-homo-estrane and process of preparation
US4191660A (en) * 1978-02-27 1980-03-04 International Flavors & Fragrances Inc. Organoleptic uses of 1-(3,3-dimethyl-2-norbornyl)-2-propanone in cationic, anionic and nonionic detergents and soaps

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Kojima et al., Tetrahedron Letters, pp. 3742-3747, 1978. *
Konishi et al., Chemistry Letters, pp. 1437-1440, 1979. *
Morton et al., J. Org. Chem., vol. 44, No. 16, 1979, 2880-2887. *
Nicolaou et al., J.C.S. Chemical Communications, pp. 1067-1068, (1978). *
Nielsen et al., Organic Reactions, vol. 16, p. 47. *
Shibasaki et al., Chemistry Letters, pp. 1299-1300, 1979. *
Shibasaki et al., Tetrahedron Letters, pp. 432-437, 1979. *
Sugie et al., Tetrahedron Letters, pp. 2607-2610, 1979. *
Wagner et al., Synthetic Organic Chemistry, p. 174 and p. 288. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004019A1 (en) * 1982-05-06 1983-11-24 Cbd Corporation Cycloaliphatic pharmaceutical compounds
US4689345A (en) * 1982-05-06 1987-08-25 Cbd Corporation Oxygenated alkyl substituted bicyclo alkanes
US4689349A (en) * 1982-05-06 1987-08-25 Cbd Corporation Anti-tumor halo bicyclo alkanones
US4855322A (en) * 1982-05-06 1989-08-08 Cbd Corporation Oxygenated alkyl substituted bicyclo alkanes
WO1985002177A1 (en) * 1983-11-08 1985-05-23 Cbd Corporation Halo bicyclo alkanones
US4681951A (en) * 1983-12-27 1987-07-21 Sagami Chemical Research Center Bicyclo(3.3.0)octene derivatives

Also Published As

Publication number Publication date
CA1142532A (en) 1983-03-08
EP0015653A1 (en) 1980-09-17
EP0015653B1 (en) 1982-01-27
JPS6228140B2 (en) 1987-06-18
JPS55105638A (en) 1980-08-13
DE3060152D1 (en) 1982-03-11

Similar Documents

Publication Publication Date Title
CH647222A5 (en) 9-DESOXY-9A-METHYLENE ISOSTERES OF PGI-2 AND METHOD FOR THE PRODUCTION THEREOF.
EP0045118A2 (en) Intermediates for the synthesis of bicyclo (2,2,1) heptanes and bicyclo (2,2,1) hept-2Z-enes
Guindon et al. Preparation of ethyl 5 (s), 6-epoxy-3 (r)-(methoxymethoxy) hexanoate: a key chiral intermediate for mevinolin and compactin.
US4292432A (en) Novel aldol derivatives and production thereof
Just et al. Synthesis of prostaglandin F1. alpha. and related substances
Grieco et al. Synthesis of mono-and bifunctional. alpha.-methylene lactone systems as potential tumor inhibitors
SUEMUNE et al. A new conversion method from (-)-limonene to nepetalactones
DE2347172A1 (en) PROSTAGLANDIN E DEEP 1 SYNTHESIS
Cantrell Reactivity of photochemically excited 3-acylthiophenes, 3-acylfurans, and the formylthiophenes and furans
US4090019A (en) Geminal prostaglandin analogs
US4107181A (en) Useful prostaglandin intermediates
US4150039A (en) 2,2'-Bis(3,4-Epoxy-5-oxotetrahydropyran)ethers
US4277401A (en) Total synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl)-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid
TANAKA et al. Synthetic Studies on a Picrotoxane Sesquiterpene, Coriamyrtin. I. The Grignard Reaction of 5-(2-Methyl-1, 3-dioxo-2-cyclopentyl) methyl-2, 5H-furanone with Isopropenylmagnesium Bromide and Stereochemistries of the Products
US4122093A (en) Process for preparing a lactone
FR2472573A1 (en) POLYCYCLIC DERIVATIVES OF ANTHRACENE AND NAPHTHACENE AND PROCESS FOR THEIR PREPARATION
US4089897A (en) Geminal prostaglandin analogs
US4985571A (en) 6-membered lactones useful as intermediates for antilipemic mevalonic acid lactones
Kigoshi et al. Novel Transformation of Formyl Groups into Hydroxyl Groups Utilizing Deformylative Autoxidation of Aldehydes.
US4214099A (en) Intermediates for synthesis of precursors for prostaglandins
Casas et al. Enantioselective production of homochiral (+)-(1R, 2S, 3S, 4S)-and (−)-(1S, 2R, 3R, 4R)-bicyclo (2.2. 1) heptane-2, 3-dicarboxylic acid, 2-methyl esters. Formal synthesis of the TXA2 antagonist S-1452.
US4052434A (en) Prostaglandin intermediates
US3907998A (en) Methods for relieving bronchial spasm with 9,15-dioxygenated prostanoic and prost-13-enoic acids and the like
DE2166797C2 (en) Optically active tricyclic lactonaldehydes and processes for their preparation
SU780435A1 (en) 3,4-dihydro-10oxy-1(2h)-phenanthrenones as semi-product in synthesis of steroids or their analogues and method of obtaining same

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE